Interrupt therapy during evaluation of patients who develop dyspnoea & fatigue after treatment initiation for pleural effusion, pulmonary oedema, anaemia, or lung infiltration; if signs or symptoms of cardiac adverse reactions develop. Permanently discontinue treatment if pulmonary arterial HTN is confirmed. Discontinue if lab or clinical findings associated w/ thrombotic microangiopathy occur. Evaluate patients who develop symptoms suggestive of pleural effusion (eg, dyspnoea or dry cough) by chest X-ray; for signs & symptoms of underlying cardiopulmonary disease prior to initiating therapy. Monitor patients w/ risk factors (eg, HTN, hyperlipidaemia, diabetes) or history of cardiac disease (eg, prior percutaneous coronary intervention, documented CAD) for chest pain, shortness of breath, & diaphoresis; HBV carriers who require treatment for signs & symptoms of active HBV infection throughout therapy & for several mth following termination of therapy. Correct hypokalaemia or hypomagnesaemia prior to therapy. Perform test to patients for HBV infection before initiating treatment. Anaemia, neutropaenia & thrombocytopaenia; bleeding/haemorrhage. Fluid retention. Potential to prolong cardiac ventricular repolarisation (QT interval). CHF/cardiac dysfunction, pericardial effusion, arrhythmias, palpitations, QT prolongation & MI. Patients taking medicinal products that inhibit platelet function or anticoagulants; who have or may develop QTc prolongation; w/ hypokalaemia or hypomagnesaemia, congenital long QT syndrome, those taking anti-arrhythmic medicinal products or other medicinal products leading to QT prolongation, & cumulative high dose anthracycline therapy; w/ uncontrolled or significant CV disease. Perform CBC wkly for the 1st 2 mth, then mthly thereafter in adults w/ advanced phase CML or Ph+ ALL; every 2 wk for 12 wk, then every 3 mth thereafter in adults & paed patients w/ chronic phase CML; prior to start of each block of chemotherapy in paed patients w/ Ph+ ALL; every 2 days until recovery during consolidation blocks of chemotherapy; echocardiography at treatment initiation in every patient w/ cardiac disease & risk factors for cardiac or pulmonary disease. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Not recommended in concomitant use w/ potent CYP3A4 inhibitors eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice; H
2 antagonist (eg, famotidine), PPI (eg, omeprazole). Concomitant use w/ CYP3A4 inducers [dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarb or herbal prep containing
Hypericum perforatum (St. John's Wort)], & substrates of narrow therapeutic index eg, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine). Administer Al-/Mg hydroxide up to, or 2 hr following administration of treatment. May affect ability to drive & use machines. Hepatic & renal impairment. Sexually active men & women of childbearing potential should use effective methods of contraception during treatment. Male patients should be counselled on semen deposition. Congenital malformations including neural tube defects. Not to be used during pregnancy. Discontinue lactation during treatment. Not recommended to use tab in paed patients weighing <10 kg. Monitor bone growth & development in paed patients. Childn <1 yr. Monitor elderly ≥65 yr for pleural effusion, dyspnoea, cough, pericardial effusion & CHF.